flâneur

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn — RApport

rapport.bio · 11,087 words · saved by 2 readers

The biotech sector is experiencing the most severe downturn of at least the last 20 years. There have been many other downturns in the more recent past, but this one is different. Here Peter Kolchinsky discusses why - and how we’ll rebound.

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn Finance Biotech May 27 Written By Peter Kolchinsky Tweet by Peter Kolchinsky, PhD Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. May 27, 2022 (This is a long piece; click here to read it in Bionic Reading format, which may for some increase reading speed and comprehension. Let us know if you like it and we may post more pieces with this option.) The biotech sector is experiencing the most severe downturn of at least the last 20 years. There have been many other d

saved by

related reading